Literature DB >> 3257763

Variable quantitation of Haemophilus influenzae type b anticapsular antibody by radioantigen binding assay.

J I Ward1, D P Greenberg, P W Anderson, K S Burkart, P D Christenson, L K Gordon, H Kayhty, J S Kuo, P Vella.   

Abstract

The measurement of antibody to Haemophilus influenzae type b capsular polysaccharide is important in the study of natural immunity and in the immunogenicity evaluation of H. influenzae type b vaccines. Several radioantigen binding assays (RABA) have been developed to measure H. influenzae type b anticapsular antibody, but recent immunogenicity data obtained with structurally similar vaccines suggest major differences in antibody quantitation in different laboratories. To evaluate interlaboratory variability in the measurement of anticapsular antibody levels, we blindly evaluated a sample of 40 pre- and postimmunization sera by eight RABAs in different laboratories. Evaluation of RABA methods revealed differences in polysaccharide antigens, radiolabeling methods, concentration and volume of antigen and antibody, and other assay methods. The reported results of assays varied significantly between laboratories (up to sixfold differences in geometric means), in part because of differences in assay sensitivity and different proportions of samples having undetectable levels of antibody (0 to 65% of specimens with undetectable levels). After standardizing the limit of sensitivity for all assays (0.125 microgram/ml), the results of all combinations of paired analyses of RABA assays correlated well (r = 0.88 to 0.99) but the geometric mean levels still varied as much as twofold. For individual sera, the differences between paired assays often were substantial (P less than or equal to 0.0001, paired t test), with some results varying as much as 64-fold. Differences were greatest for lower levels of antibody. There was good comparability and interlaboratory reproducibility of some assays but not of others. Intrinsic or extrinsic labeling of the antigen was not a major determinant of comparability. In most instances, the current variation in the quantitation of antibody levels by these assays precludes interassay comparisons. A standardized measurement of antibody needs to be developed to adequately compare results between different H. influenzae type b immunogenicity studies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257763      PMCID: PMC266190          DOI: 10.1128/jcm.26.1.72-78.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  A quantitative immunochemical measure of the primary interaction between I BSA and antibody.

Authors:  R S FARR
Journal:  J Infect Dis       Date:  1958 Nov-Dec       Impact factor: 5.226

2.  Responses of children immunized with the capsular polysaccharide of Hemophilus influenzae, type b.

Authors:  D H Smith; G Peter; D L Ingram; A L Harding; P Anderson
Journal:  Pediatrics       Date:  1973-11       Impact factor: 7.124

3.  Characterization of human antibody to polyribophosphate, the capsular antigen of Hemophilus influenzae, type B.

Authors:  R B Johnston; P Anderson; F S Rosen; D H Smith
Journal:  Clin Immunol Immunopathol       Date:  1973-01

4.  Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies.

Authors:  J B Robbins; J C Parke; R Schneerson; J K Whisnant
Journal:  Pediatr Res       Date:  1973-03       Impact factor: 3.756

5.  Immunity to disease caused by Hemophilus influenzae type b. II. Specificity and some biologic characteristics of "natural," infection-acquired, and immunization-induced antibodies to the capsular polysaccharide of Hemophilus influenzae type b.

Authors:  R Schneerson; L P Rodrigues; J C Parke; J B Robbins
Journal:  J Immunol       Date:  1971-10       Impact factor: 5.422

6.  Lack of comparability between commonly used serological assays of immune response to Haemophilus influenzae vaccine.

Authors:  K M Edwards; M D Decker; P Palmer; C R Porch; S H Sell; P F Wright
Journal:  J Infect Dis       Date:  1987-02       Impact factor: 5.226

7.  Immunochemical variables affecting radioantigen-binding assays of antibody to Haemophilus influenzae type b capsular polysaccharide in childrens' sera.

Authors:  P Anderson; R A Insel; S Porcelli; J I Ward
Journal:  J Infect Dis       Date:  1987-10       Impact factor: 5.226

8.  Factors influencing immunogenicity and safety of two Haemophilus influenzae type b polysaccharide vaccines in children 18 and 24 months of age.

Authors:  D P Greenberg; J I Ward; K Burkart; P D Christenson; L Guravitz; S M Marcy
Journal:  Pediatr Infect Dis J       Date:  1987-07       Impact factor: 2.129

9.  Human serum activities against Hemophilus influenzae, type b.

Authors:  P Anderson; R B Johnston; D H Smith
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

10.  Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein.

Authors:  M S Einhorn; G A Weinberg; E L Anderson; P D Granoff; D M Granoff
Journal:  Lancet       Date:  1986-08-09       Impact factor: 79.321

View more
  7 in total

Review 1.  Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Authors:  Catherine M Wernette; Carl E Frasch; Dace Madore; George Carlone; David Goldblatt; Brian Plikaytis; William Benjamin; Sally A Quataert; Steve Hildreth; Daniel J Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

2.  Interlaboratory study evaluating quantitation of antibodies to Haemophilus influenzae type b polysaccharide by enzyme-linked immunosorbent assay.

Authors:  D V Madore; P Anderson; B D Baxter; G M Carlone; K M Edwards; R G Hamilton; P Holder; H Käyhty; D C Phipps; C C Peeters; R Schneerson; G R Siber; J I Ward; C E Frasch
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

3.  Randomized, controlled, multicenter study of the immunogenicity and safety of a fully liquid combination diphtheria-tetanus toxoid-five-component acellular pertussis (DTaP5), inactivated poliovirus (IPV), and haemophilus influenzae type b (Hib) vaccine compared with a DTaP3-IPV/Hib vaccine administered at 3, 5, and 12 months of age.

Authors:  Timo Vesikari; Sven Arne Silfverdal; Florence Boisnard; Stéphane Thomas; Grace Mwawasi; Donna Reynolds
Journal:  Clin Vaccine Immunol       Date:  2013-08-21

4.  Complement activation by polyclonal immunoglobulin G1 and G2 antibodies against Staphylococcus aureus, Haemophilus influenzae type b, and tetanus toxoid.

Authors:  R G Bredius; P C Driedijk; M F Schouten; R S Weening; T A Out
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

5.  Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay.

Authors:  G M Carlone; C E Frasch; G R Siber; S Quataert; L L Gheesling; S H Turner; B D Plikaytis; L O Helsel; W E DeWitt; W F Bibb
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

6.  Comparison between radioimmunoassay and direct and indirect enzyme-linked immunosorbent assays for determination of antibodies against Haemophilus influenzae type b capsular polysaccharide.

Authors:  T Lagergård; B Trollfors; B A Claesson; R Schneerson; J B Robbins
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

7.  Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay.

Authors:  L L Gheesling; G M Carlone; L B Pais; P F Holder; S E Maslanka; B D Plikaytis; M Achtman; P Densen; C E Frasch; H Käyhty
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.